Abstract 2021
- P001 Succinate, a gut microbiota-derived metabolite, modulates the inflammatory status of the creeping fat in Crohn’s disease.
- P002 Methodological development of single-cell phenotyping and spatial analysis of intestinal leukocyte, stromal and epithelial cell populations in inflammatory bowel disease formalin fixed paraffin embedded tissue by Hyperion imaging mass cytometry
- P003 HDAC7 Controls Differentiation and Regeneration in the Intestinal Epithelium
- P004 Critical paralog proteins has a cell-type specific rewiring role in Ulcerative Colitis associated signalling processes
- P005 Cytokine mediated intercellular communication in inflammatory bowel disease
- P006 Host-genetics, dysbiosis, and clinical history explains fecal metabolic alterations in patients with Inflammatory Bowel Disease
- P007 Identification and characterisation of intestine-derived circulating resident memory T cells (ex-Trm) in health and Inflammatory Bowel Disease
- P008 Store-operated calcium entry controls immune cell function and activation in Inflammatory Bowel Disease
- P009 Disease classifier and microbial dysbiosis index tools cross-predict various pathogenic conditions due to general microbial signal
- P010 GSDMB-mediated pyroptosis exacerbates intestinal inflammation by destroying intestinal epithelium in Crohn’s disease
- P011 Serum adhesion G protein coupled receptor levels are associated with disease activity in pediatric patients with Crohn’s disease
- P012 Low frequencies of circulating inhibitory TIGIT+CD38+ effector T cells identify an immunologically distinct subgroup of pediatric patients with severe Crohn's disease
- P013 Potential Role of Epithelial Protein Disulphide Isomerases in Crohn’s Disease Fibrosis
- P014 Untargeted serum metabolome in longitudinal Crohn's Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin
- P015 Differential expression in colitis-associated cancer compared to Crohn´s disease and ulcerative colitis
- P016 SZN-1326, a Wnt signal activator, is more efficacious than cyclosporine A in an acute DSS model
- P017 Small bowel transcriptomics define similarities and divergent pathways between Crohn, environmental enteric dysfunction (EED), and celiac diseases, implicating role for the microbiome in the pathogenesis
- P018 Myeloid diversity in inflammatory bowel disease revealed by single-cell transcriptomics
- P019 Differential effects of first-line IFX and conventional treatment on inflammatory serum proteins of paediatric moderate- to-severe Crohn’s disease patients.
- P020 Mapping the changing intercellular communication and its downstream effect in Ulcerative Colitis
- P021 Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course
- P022 Pathologic involvement of the farnesoid X receptor/fibroblast growth factor 19 axis to the Crohn’s disease early postsurgical recurrence.
- P023 SZN-1326, a Wnt agonist, improved epithelial healing and ameliorated colitis in a chronic DSS model, in stark contrast to anti-TNF and anti-IL-12/23p40 antibodies
- P024 Development of a treatment for short bowel syndrome using small intestinal organoids
- P025 Identification and validation of predictors for tofacitinib through supervised and unbiased approaches in Inflammatory Bowel Disease
- P026 Microbial Diversity is affected by Cognitive Behavioral and Mindfulness-Based Stress Reduction and accompanied by an Inflammatory Response in Patients with Crohn’s Disease
- P027 Epithelial cells of patients with ulcerative colitis do not show an increased sensitivity after microbiota stimulation compared to non-IBD controls
- P028 The Apa I polymorphism in the Vitamin D receptor gene is associated with a stricturing behaviour in Crohn´s disease patients
- P029 Activation of FXR restores expression of genes dysregulated in human IBD and suppresses TNFa and IL-6 signaling pathways in adoptive transfer colitis model
- P030 SUCNR1 mediates inflammasome activation: Relevance in Ulcerative Colitis
- P031 Class A1 scavenger receptor mediates macrophage polarization and apoptotic progression in a murine dextran sulfate sodium-induced colitis
- P032 MiR-511 deficiency aggravates T cell transfer colitis in mice
- P033 Dendritic cells from patients with active IBD imprint pro-inflammatory α4β7+CLA+ T cells with potential for gut and skin homing
- P034 Human primary 2D culture as a tool to explore JAK1 pathway inhibition in the intestinal epithelium using siRNA technology
- P035 Potential biomarkers for diagnosis through proteomics, in patients with Inflammatory Bowel Disease
- P036 MicroRNA composition of colon crypt-top and crypt-bottom epithelial cells in Ulcerative Colitis
- P037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor
- P038 Microbial regulation of T-cell fate towards regulatory profiles during T-cell transfer induced colitis
- P039 New molecular markers of the development of ulcerative colitis
- P040 USP16 regulates p65 activation in macrophages and promotes the inflammatory-carcinoma transformation process in IBD patients
- P041 CDKN2B-AS1 (ANRIL) expression is decreased in Inflammatory Bowel Disease epithelia and in Celiac, and its reduction is linked with induced cells proliferation
- P042 Diagnostic and prognostic value of soluble adhesion molecules in patients with ulcerative colitis
- P043 Succinate receptor (SUCNR1) mediates leukocyte-endothelial cell interactions induced by TNFa
- P044 Transcriptome analysis identifies dysregulated pathways and targets for therapy in patients undergoing surgical resection for Crohn’s disease
- P045 Oncostatin M induces strong fibrotic and chemokine responses from primary colonic subepithelial myofibroblasts
- P046 Disease modelling of Inflammatory Bowel Disease by human colon organoids
- P047 The ATG16L1 T300A polymorphism in Crohn's Disease patients leads to abnormal autophagy flux in dendritic cells
- P048 Intestinal inflammation and microbiome diversity are conserved more in consecutive pregnancies among women with inflammatory bowel disease compared to healthy controls
- P049 Development of human embryonic stem cell-derived intestinal organoids for in vitro studies on intestinal inflammation and fibrosis
- P050 Effect of biological treatments (anti-TNFs) in the creeping fat of Crohn’s disease patients
- P051 Macrophages as a source of Notch Ligands in Crohn's disease: implications in fibrosis
- P052 Comprehensive proteomic profiling of stool from UC and CD patients reveals expected and novel mucosal pathobiology, enabling identification of candidate non-invasive biomarkers to monitor mucosal disease activity
- P053 Overabundance of Lactobacillus species in gut microbiota of IBD patients
- P054 Modulation of the Gut Microbiota-Farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice
- P055 Brain-Immune Axis Regulation is Responsive to Cognitive Behavioral and Mindfulness-Based Stress Reduction in Crohn’s Disease
- P056 Crohn’s Disease associated fibrosis modulates the expression of collagen receptors
- P057 CRL4DCAF2 promotes cell proliferation and limits the development of colitis
- P058 Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
- P059 GB004 drives protective effects on immune cells and epithelial cells using human ex vivo monolayer and co-culture systems
- P060 A2B adenosine receptor deficiency ameliorates chronic murine Crohn’s-like-ileitis.
- P061 Immune cell infiltrations of myenteric plexus in IBD – characterization and implications
- P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease
- P063 The immunological landscape of intestinal fibrosis in Crohn’s Disease.
- P064 3-oxo-C12:2, a Quorum Sensing molecule from the gut, exerts anti-inflammatory effects through a bitter taste receptor
- P065 Conservation of breast milk cytokine profiles in consecutive pregnancies of women with inflammatory bowel disease
- P066 Exploration of critical molecules for optimizing treatment by analyzing inflammatory cytokines in the intestinal mucosa of patients with Inflammatory Bowel Disease
- P067 The effect of a probiotic mix on mucosal healing and fibrotic responses in healthy colonic subepithelial myofibroblasts.
- P068 The combination of JAK1 and TPL2 or IRAK4 inhibitors is more effective than single agents in reducing TLR-mediated cytokine responses in human monocyte populations
- P069 Artificial intelligence (AI)-filtered Videos for Accelerated Scoring of Colonoscopy Videos in Ulcerative Colitis Clinical Trials
- P070 Efficacy of a novel non-covalent oral small molecule Nrf2 activator in a rat model of Inflammatory Bowel Disease
- P071 Crohn’s Disease is associated with elevated levels of the pro-inflammatory CXCR3 ligands (CXCL9, 10 and 11) with an associated reduction in Paneth cell derived antimicrobial peptides in ex-vivo ileal biopsies
- P072 The involvement of extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT) and Nicotinate Phosphoribosyltransferase (eNAPRT) in inflammatory bowel disease
- P073 An increased autophagy and decreased apoptosis is detected in intestinal fibroblasts from Crohn’s Disease patients
- P074 Crohn’s disease clinical data standards: Adoption and implementation to promote data sharing and reuse.
- P075 Multidimensional assessment of interoceptive abilities, emotion processing and the role of early life stress in Inflammatory Bowel Disease
- P076 The endocannabinoid system in the intestinal biopsies of children with Inflammatory Bowel Disease
- P077 What matters to Ulcerative Colitis patients when they make treatment decisions? A systematic review
- P078 Proteomics and Lipidomics Analysis Revealed Alterations of Complement Activation and Lipid Metabolism in peripheral blood mononuclear cells of Inflammatory Bowel Disease Patients
- P079 Valproic acid increases MiR449a expression in intestinal mucosa from patients with inflammatory bowel disease
- P080 Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
- P081 Resolvin D2 attenuates colonic inflammation of Crohn’s disease patients
- P082 Assessment of anti-inflammatory effect of high acetate administration in UC patient-derived epithelial monolayer cultures
- P083 High prevalence of ulcerative appendicitis in UC patients without colonic disease activity
- P084 C-Reactive Protein Correlates with Tumor Necrosis Factor-α in Ulcerative Colitis
- P085 Expression profiling of Wnt pathway genes in colon biopsies of patients with Ulcerative Colitis
- P086 Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon immune dysregulation and intestinal permeability in a stress-induced colonic inflammation
- P087 The role of bile acids in mediating fibrosis in inflammatory bowel disease
- P088 Neurotuberculosis in a patient with Ulcerative Colitis using adalimumab for a long period in Brazil
- P089 IFNγ-macrophages could mediate EMT in Crohn’s disease
- P090 Risk of Rectal Cancer after Colectomy in Patients with Inflammatory Bowel Disease – A Nationwide Population-based Danish Cohort Study 1978-2018
- P091 Switching to TNFi versus non-TNFi biologics in Crohn’s Disease patients: Real-world outcomes from a German claims data analysis
- P092 Development and evaluation of i-Tracker Ustekinumab and i-Tracker Anti-ustekinumab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with ustekinumab
- P093 COVID-19 lockdown and mental health burden in Inflammatory Bowel Disease paediatric patients: a case-control study
- P094 Textbook outcome in Inflammatory Bowel Disease surgery
- P095 Initial disease course in a Belgian, prospective inception cohort of patients with inflammatory bowel disease: the PANTHER cohort
- P096 Which patients with known Crohn’s disease after an ileo-colonoscopy will benefit most from small bowel capsule endoscopy?
- P097 Abnormal frailty screening is independently associated with both all-cause and disease-related hospital admissions in older patients with inflammatory bowel diseases.
- P098 has been withdrawn
- P099 Evaluation of endoscopic mayo score with an artificial intelligence algorithm
- P100 Higher yield of serrated and adenomatous dysplasia detected with chromoendoscopy when compared with high-definition in patients with Primary Sclerosing Cholangitis and Inflammatory colitis.
- P101 Fecal calprotectin is increased among patients with pouchitis and increases with increasing endoscopic subscores: Real-world data from a prospectively collected database
- P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
- P103 Minimal Clinically Important Difference (MCID) for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool
- P104 Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU
- P105 Coping in Inflammatory Bowel Disease: insights from the Crohn’s and Colitis UK national survey
- P106 Cromoendoscopy versus second generation Narrow band Imaging for dysplasia detection in IBD. An interim analysis of a prospective randomized control trial.
- P107 Monitoring inflammatory bowel disease in clinical practice using gut microbial markers in faecal samples. Prospective study in a clinical cohort.
- P108 has been withdrawn
- P109 Impact of ethnicity on colorectal cancer incidence in a cohort of colitis-associated dysplasia patients
- P110 Symptomology and most bothersome symptoms among pediatric Crohn’s disease and ulcerative colitis patients: Results from a physician and patient survey
- P111 Cross-sectional imaging is highly sensitive in detecting endoscopic post-operative recurrence in Crohn’s disease patients
- P112 Impact of the SARS-COV2 pandemic on patients with inflammatory bowel disease - Preliminary results of a prospective, single-center study
- P113 Automatic detection of colonic ulcers and erosions in colon capsule endoscopy images using a convolutional neural network
- P114 Frequent work productivity and activity impairment in caregivers of children with inflammatory bowel disease: a project of the prospective PIBD-SETQuality inception cohort study
- P115 Chronic pouchitis and Crohn's disease of the pouch after ileal pouch-anal anastomosis : incidence and risk factors
- P116 Development of a new patient-reported outcome measure for patients with complex cryptoglandular fistulas
- P117 Patient perceptions about causes of flare in IBD: results from the baseline dataset of the PREdiCCt study
- P118 External validation of model predicting early-onset surgery in Crohn’s Disease patients
- P119 There is minimal agreement on the recognition of deep ulcers as seen on endoscopy in patients with Inflammatory Bowel Disease: a national survey
- P120 Developing “My quality of life” programme based on ICHOM Standard Set for IBD: 1-year results
- P121 The study of the hypercoagulable state in Crohn disease: Results of a prospective comparative study.
- P122 Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department
- P123 Type I collagen degradation fragments and type IV collagen formation/degradation ratio are serological biomarkers for stricturing (Montreal B2) Crohn's disease
- P124 Gastroenteropancreatic Neuroendocrine Neoplasms in patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series
- P125 Could gut microbiota metagenomic analysis improve diagnosis in paediatric Inflammatory Bowel Disease population?
- P126 Older adults with acute severe ulcerative colitis have similar steroid failure and colectomy rates as younger adults
- P127 Assessing the vaccination and immunization status in a Paediatric Inflammatory Bowel Disease diagnosis
- P128 Depression, anxiety and stress among Inflammatory Bowel Disease patients during COVID-19: A UK cohort study
- P129 IBD care in the UK: A comprehensive, novel service assessment with feedback from 10,222 patients and 166 NHS organisations to inform a vision for quality improvement
- P130 Adhesions are not always the enemy: pouch volvulus
- P131 Serum Proteomics and Intestinal Ultrasound Differentiates Fibrostenotic and Inflammatory Crohn’s Disease
- P132 Uncovering blood biomarkers of Inflammatory Bowel Diseases by Raman spectroscopy and FAP dosage: toward a noninvasive triage of patients in first care diagnostic
- P133 Clinical and ultrasonographic enthesitis in inflammatory bowel disease patients with and without psoriasis
- P134 Ultrasonographic scores for Crohn’s disease activity assessment – still lag behind CEUS
- P135 Proximal Extension of lower rectal Ulcerative Proctitis
- P136 Management of patients with Inflammatory Bowel Disease and their outcome during the first wave of Covid-19 pandemics.
- P137 Preliminary validation of a multi-stage machine learning algorithm to assess histological inflammation in inflammatory bowel disease
- P138 Platelet-to-lymphocyte ratio index: a reliable tool for non-invasive assessment of endoscopic activity in small bowel Crohn’s Disease
- P139 Significant Changes In Routine Biochemical Markers Occur Up To 5 Years Prior To Inflammatory Bowel Disease Diagnosis: A Case-Control Study
- P140 Predicting Non-Responsiveness to Iron Therapy in Anaemic Children with Inflammatory Bowel Disease
- P141 IBUS-SAS for Crohn’s disease ultrasound activity: initial validation and research of the optimal cut-off score
- P142 Role of e-health in the management of Inflammatory Bowel Disease: A systematic review and meta-analysis
- P143 Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown
- P144 Clock gene expression levels inversely correlate with disease activity in ulcerative colitis and Crohn’s disease
- P145 Inflammatory Bowel Disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: results of a multicentric European study during the first COVID-19 outbreak (COVIBD-Surg)
- P146 The Toronto IBD global endoscopic reporting (TIGER) score demonstrates significant correlation with fecal calprotectin, CRP and IBD Disk in Crohn's disease patients
- P147 Progression to biologic treatment in very early onset inflammatory bowel disease patients- a long term follow up retrospective study
- P148 ANA and Anti-dsDNA antibody enabling the prediction of inflammatory arthritis in inflammatory bowel disease.
- P149 Application of revised Pediatric Inflammatory Bowel Disease (PIBD) classes criteria to the Korean PIBD patients
- P150 Histologic features predicting prognosis and their relationship with endoscopic findings in Ulcerative Colitis patients with mucosal healing
- P151 Validation of the MaRIA Score in pediatric patients.
- P152 Bowel ultrasound as an early monitoring tool to assess disease activity in Crohn’s disease patients after induction therapy with infliximab
- P153 IBD patients’ treatment preferences are heterogeneous, but largely affected by the avoidance of abdominal pain and side effects (P-POWER IBD study)
- P154 Faecal calprotectin and patient reported disease control of IBD: results from the baseline dataset of the PREdiCCt study
- P155 Bowel preparation is valued more than colorectal cancer risk and interval by patients in colitis-associated colorectal cancer surveillance: a discrete choice experiment
- P156 Translation into Spanish, adaptation and validation of the "IBD- control", a short validated English PRO (patients reported outcomes) questionnaire: the EII-Control
- P157 Microbiome Analysis Reveals That Ralstonia is Responsible for Decreased Renal Function in Patients with Ulcerative Colitis
- P158 Diagnostic yield of different imaging modalities (VCE, MRE and SBUS) in paediatric Inflammatory Bowel Disease patients
- P159 Patients with Inflammatory Bowel Disease Present with Lower Trabecular Bone Scores
- P160 Can the Lemann index at diagnosis predict the risk of early surgery in Crohn's disease?
- P161 The impact of biologic therapies on Extra-Intestinal Manifestations in Inflammatory Bowel Disease: a multicentre observational study.
- P162 Microscopic inflammation in limited Ulcerative Colitis at diagnosis: can a single histological feature predict prognosis?
- P163 The impact of the COVID-19 pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease in The Netherlands.
- P164 Celiac Disease among a large cohort of inflammatory bowel disease patients: epidemiology and outcome implications
- P165 Non-invasive biomarkers of type III collagen cross-linking reflects fibrolysis in patient with luminal CROHN’S DISEASE
- P166 Impact of consultation frequency and time to diagnosis on subsequent Inflammatory Bowel Disease outcomes
- P167 Sexual dysfunction and associated factors in young patients with Crohn's disease
- P168 Depression and fatigue dependent variation of gut microbiome in patients with active Inflammatory Bowel Disease
- P169 Vitamin D levels are inversely associated with inflammation in pediatric InflammatoryBowel Disease patients
- P170 Correlation between health-related quality of life and smartphone-based self-assessment of activity index in patients with ulcerative colitis
- P171 Immune-mediated diseases (IMID) and COVID-19: results from an observational retrospective multicenter study
- P172 Clinical characteristics of newly diagnosed adult patients with Crohn's disease in Japan: Interim analysis of Inception cohort registry study of patients with Crohn's disease (iCREST-CD)
- P173 Subfertility in young women and men patients with Crohn´s disease
- P174 Defining Crohn's Disease Strictures Using Intestinal Ultrasound Compared to Histopathology
- P175 Complete endoscopic healing is associated with lower disability than partial mucosal healing in Crohn’s disease: a prospective multicentric study.
- P176 Patient preferences in steroid resistant ulcerative colitis – a discrete choice experiment survey
- P177 Adherence to a bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn’s disease and factors affecting the image quality
- P178 Remote monitoring as an effective management strategy in inflammatory bowel disease: the lesson from COVID-19 pandemic
- P179 Treatment decisions and biologic adoption rates in newly diagnosed Crohn's disease in Japan
- P180 Endoscopic scoring systems for Crohn’s Disease and Ulcerative Colitis and their correlation with histological and clinical outcomes
- P181 Patient-led remote intracapillary pharmacokinetic sampling (fingerPRICKS) for therapeutic drug monitoring in patients with Inflammatory Bowel Disease
- P182 Bowel wall thickness as seen on point-of-care intestinal ultrasound correlates with endoscopic severity in children with Inflammatory Bowel Disease: A North American diagnostic cross-sectional study
- P183 Risk of eating disorders in italian children and adolescents with Inflammatory Bowel Disease: results of a multicenter nationwide study
- P184 Disease activity in Inflammatory Bowel Disease patients is associated with increased liver fat content during follow-up
- P185 Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain
- P186 Inflammatory Bowel Disease Care in the Covid-19 pandemic era: Experience from a Tunisian gastroenterology department
- P187 Change in Urgency Status Among Ulcerative Colitis Patients: Understanding the Impact of Treatment Changes from the Corrona Inflammatory Bowel Disease Registry
- P188 Artificial Intelligence and Colon Capsule Endoscopy: Automatic detection of colonic mucosal lesions and blood using a convolutional neural network
- P189 has been withdrawn
- P190 Ileo-caecal Crohn’s Disease; medical or surgical management. Cost and outcomes.
- P191 Non-specific terminal ileitis: prevalence, clinical course and association with later diagnosis of Crohn’s disease
- P192 Frequency of hereditary and acquired thromboembolic complications in patients with inflammatory bowel diseases in Moscow Clinical Scientific Center named after A.S. Loginov
- P193 Assessement of cumulative bowel damage using Lemann index and MaRIA score in surgically naive patients with Crohn's disease
- P194 Alexithymia traits are associated with symptom severity and disease activity in IBD patients
- P195 Predictors of colectomy in patients with acute severe ulcerative colitis: single-center retrospective analysis.
- P196 Colon-involving versus non-colon-involving Crohn’s disease classification: is the Montreal classification outdated?
- P197 The effect of a positive family history on the phenotype and course of paediatric Inflammatory Bowel Disease
- P198 Practical deep learning tool for the scoring of ulcerative colitis disease activity in central reading
- P199 Analysis of clinical features of asymptomatic perianal fistulizing Crohn's disease
- P200 Celiac disease (CD) and CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) association
- P201 Evaluation of the role of anti-TNF in stabilizing the progression of intestinal lesions in Crohn's disease using the Lemann Index
- P202 De novo Inflamatory Bowel Disease after solid organ transplantation
- P203 Sexual Dysfunction in Chronic Inflammatory Bowel Disease: Myth or Reality?
- P204 Elevated Fecal Calprotectin Levels Predict Flare-up in Patients with Inflammatory Bowel Disease During International Air Travel
- P205 Influencing factors of Sleep quality in patients with Crohn's Disease
- P206 Paediatric Genital Crohn’s Disease: Presentation and Treatment, a combined case series
- P207 Clinical outcome of patients with Ulcerative colitis after anti-TNF discontinuation -\t10 years follow up
- P208 Differentiating intestinal tuberculosis from Crohn's Disease: External validation of a new nomogram
- P209 Prevalence and risk factors for fatigue in chronic inflammatory bowel disease
- P210 Healthcare resources utilisation prior to the diagnosis of ulcerative colitis and Crohn’s disease
- P211 Pseudopolyps are associated with increased fecal calprotectin levels in patients with Inflammatory Bowel Disease in clinical and endoscopic remission.
- P212 Assessment of Crohn's disease activity using global MaRIA score in patients with ileal and ileocolonic disease
- P213 Having Inflammatory Bowel Disease Negatively Impacts Household and Family Life
- P214 Faecal S100A12 as a non-invasive marker of inflammatory activity in pediatric Inflammatory Bowel Disease
- P215 Blood-based prognostic biomarkers in Crohn’s patients treated with biologics: a new promising tool to predict endoscopic outcomes
- P216 Comparative Assessment C-reactive Protein Between a Point-of-Care Testing and Current Standard of Care (Immunonephelometric testing)
- P217 Clostridium Difficile Infection as a cause of severe outcomes in patients with Inflammatory Bowel Disease
- P218 Assessment of the degree of intestinal destruction in Crohn's disease at the time of diagnosis
- P219 An application of artificial intelligence in Inflammatory Bowel Disease detection
- P220 Patient-entered symptoms scores collected using a new IBD patient portal correlate closely with clinical assessment and can optimise delivery of IBD care
- P221 Crohn’s disease patients unable to complete preoperative mechanical bowel preparation have increased risk of anastomotic complications: results of a prospective observational study
- P222 Heart rate variability is a predictor to disease exacerbation in paediatric Inflammatory Bowel Disease
- P223 Degree of Histological Activity is not Associated with Vedolizumab Therapy Outcome in Ulcerative Colitis
- P224 Regular physical activity on IBD patients: impact on IBD natural history and related comorbidities
- P225 Impact of Inflammatory Bowel Diseases on patients working life
- P226 Does faecal Calprotectin help differentiate inflammatory from fibrous stenosis in Crohn’s disease?
- P227 Timing of acute severe colitis in the course of an inflammatory bowel disease: is it a prognostic factor?
- P228 Prehabilitation strategies prior to ileocolonic resection in Crohn’s disease in a prospective cohort study: a missed window of opportunity?
- P229 Standardization of Quantum Blue® rapid TDM assays with WHO international standards for adalimumab and infliximab
- P230 Development of a Japanese version of the IBD Self-Efficacy Scale and evaluation of its current status in Japan
- P231 Work productivity loss in perianal crohn's disease
- P232 Assessing effectiveness and patient perceptions of a novel electronic medical record for the management of inflammatory bowel disease.
- P233 Sleep Disorders and Chronic Inflammatory Bowel Disease: What's the Connection?
- P234 Association between anti-TNFα drug levels and drug-induced lupus in patients with Inflammatory Bowel Disease
- P235 Major Depression in patients with Crohn's disease and its relationship with clinical activity and disease’s phenotype.
- P236 Low Social support and distinct anxiety as a crucial feature in depressive IBD patients
- P237 Prevalence of dysplasia and colorectal cancer in Ulcerative Colitis patients from a referral center in Latin America
- P238 Enteropathy associated T-cell lymphoma as a diagnostic challenge in young patient with Crohn’s disease
- P239 A study to evaluate uptake of PROMS for IBD patients on Biologics : a sample United Kingdom district general hospital experience.
- P240 Clinical diagnostics of fecal calprotectin: a comparative study of a semi-quantitative rapid test and a quantitative lab test
- P241 Gastrointestinal ultrasound instead of magnetic resonance enterography: Large potential cost savings with limited clinical downsides
- P242 Newly diagnosed Inflammatory Bowel Disease patients referred via the Straight To Test Lower GI two week wait pathway, Single Centre Study.
- P243 Elevated presepsin levels are a marker of sepsis risk in patients with inflammatory bowel diseases receiving therapy of TNF-α blockers.
- P244 Clinician preferences in treating steroid resistant ulcerative colitis: a discrete-choice experiment (DCE) survey
- P245 Evaluation of quality of life in patients with perineal Crohn’s disease: a monocentric Tunisien study
- P246 Development of a new Inflammatory Bowel Disease Patient Identifier shortens time to clinic review and initiation of treatment
- P247 Carotid Plaque Assessment reclassifies patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk
- P248 Assessment of health-related quality of life of paediatric Inflammatory Bowel Disease patients through the IMPACT-III questionnaire
- P249 What’s the role of anti-TNF α in correcting anemia in Crohn’s disease?
- P250 Does Ethnicity Influence Patient’s Preferences for Treatment Outcome? The Israeli Experience
- P251 Antiphospholipid antibodies in Crohn's disease: Results of a prospective single-center study
- P252 Medication adherence in inflammatory bowel diseases in the era of biotherapies
- P253 A qualitative study exploring meaningful improvement in bowel urgency among adults with moderate to severe Ulcerative Colitis.
- P254 Factors that may predict the need for infliximab optimization in Crohn's disease
- P255 Efficacy and safety of a restrictive ferric carboxymaltose infusion strategy for iron deficiency anemia in inflammatory bowel disease patients.
- P256 High disease burden of CROHN'S DISEASE (CD) in a Latin American IBD reference center
- P257 Assessment of the nutritional status of pediatric Inflammatory Bowel Disease patients according to disease activity.
- P258 Rates of admission of acute IBD flares during the COVID-19 pandemic in a tertiary healthcare setting
- P259 Safety, tolerability and pharmacokinetics of BT051, an oral inhibitor of neutrophil migration and activation in clinical development for Inflammatory Bowel Disease
- P260 An analysis of non-melanoma skin cancer rates in the tofacitinib Ulcerative Colitis clinical programme
- P261 Predictors and outcomes of ustekinumab dose escalation to every 4 or every 6 weeks in ulcerative colitis: a multicenter cohort study in the United States
- P262 Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry
- P263 Influence of Crohn´s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study
- P264 Impact of the HLA-DQ1*05 alelle on the initial response to infliximab in patients with Inflammatory Bowel Disease
- P266 The impact of vedolizumab and ustekinumab on arthropathy and arthralgia in IBD patients: a real-life multicentric cohort study
- P267 Sequencing of anti-TNF agents and gut-selective anti-lymphocyte trafficking (GSALT) therapy in the treatment of Crohn’s disease (CD)
- P268 Ileal Pouch-Anal Anastomosis Complications and Pouch Failure: A Systematic Review and Meta-Analysis
- P269 Real-world impact of biological therapies on work impairment and quality of life in Inflammatory Bowel Disease patients.
- P270 Mesenchymal stromal cells contribute to the recovery of secondary loss of response to infliximab in patients with ulcerative colitis
- P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study
- P272 Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort
- P273 The duration of clinical remission in patients with Crohn's disease depends on the frequency of administration of mesenchymal stromal cells of the bone marrow
- P274 Drug utilization of biologic therapy in Crohn’s disease and ulcerative colitis: A population based Danish cohort study 2015-2018
- P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience
- P276 Influence of vedolizumab on extraintestinal manifestations in Inflammatory Bowel Disease: a nationwide multicenter study of the GETECCU Eneida registry
- P277 Frequency and effectiveness of empirical anti-TNF dose intensification in Inflammatory Bowel Disease: systematic review with meta-analysis
- P278 Type IV collagen formation/degradation ratio predicts response to infliximab induction therapy in patients with Ulcerative Colitis
- P279 Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study)
- P280 Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies
- P281 Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel Disease
- P282 High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel disease
- P283 Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and improvement in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study.
- P284 Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG)
- P285 A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn’s disease
- P286 Ustekinumab for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
- P287 has been withdrawn
- P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease
- P289 A French nationwide prospective study on patients with Crohn’s disease and ulcerative colitis treated with Infliximab-biosimilar CT-P13 in a real-life setting: two-year follow-up of the ReFLECT study
- P290 Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in Inflammatory Bowel Disease
- P291 Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
- P292 Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysis
- P293 Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study
- P294 AMT-101, a gut selective oral IL-10 fusion: results from a Phase 1b study in patients with active Ulcerative Colitis
- P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
- P296 Stopping 5-aminosalicylic acid in patients with ulcerative colitis who are in clinical remission does not increase risks of flare
- P297 HLA-DQA1*05 allele and its association with the secondary loss of response to infliximab in patients with Inflammatory Bowel Disease.
- P298 Budesonide MMX versus Prednisolone for Ulcerative Colitis: Comparative outcomes from a British retrospective multi-centre study
- P299 Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel Disease
- P300 Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. The STRIDENT Randomised Controlled Trial
- P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trial
- P302 Serum IL-6 is associated with treatment refractoriness in acute severe ulcerative colitis
- P303 Local Application of Autologous Platelet-rich Plasma leads to Sustained Healing of Crohn`s Perianal Fistulae – One Year follow-up Results from a Single Center Pilot Study.
- P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases
- P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
- P306 MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects
- P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn’s disease
- P308 Effectiveness and Safety of tofacitinib for the Treatment of Ulcerative Colitis: A Single-Arm Meta-analysis of Observational Studies
- P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD.
- P310 Is ileoanal pouch excision a destination therapy for Inflammatory Bowel Disease? Data from a quaternary pouch referral center
- P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
- P312 Erythrocyte methotrexate polyglutamate concentrations in patients with Crohn's Disease: towards a new therapeutic drug monitoring tool
- P313 Long-term durability and safety of anti-TNF agents compared with change to a different mechanism of action as a second-line biological treatment after first anti-TNF failure in Crohn´s disease: results from the Andalusian CambiaCrohn study
- P314 TNF gene activation used as criterion to discontinue biologic therapy – A patient series introducing the NovaPrime TNF kit
- P315 Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis
- P316 Human neutrophil elastase derived fragment of calprotectin (S100a9) is a serum biomarker (CPa9-HNE) for monitoring of anti-TNFα treatment response in Crohn’s disease
- P317 Societal cost-of-illness of Inflammatory Bowel Disease has rapidly increased over the years and differs between continents: A systematic review
- P318 Intra-dermal with topical imiquimod pre-treatment versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients: a double-blind randomized controlled trial
- P319 Impact of biological agents on postoperative complications in inflammatory bowel disease: a multicentre study of GETECCU
- P320 Combined mesenchymal stromal cells and anti-cytokine therapy of perianal Crohn's disease
- P321 Cessation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Patient Data Meta-Analysis of 323 patients from 12 studies
- P322 Hepatitis B reactivation under biologic therapy in patients with HBsAg negative phase of chronic HBV infection
- P323 Efficacy and safety of tofacitinib treatment for one year in Japanese patients with Ulcerative Colitis in a specialized Inflammatory Bowel Disease center
- P324 Predictors of corticosteroid-free remission after initiation of ustekinumab for ulcerative colitis: a real-world, multicenter cohort study in the United States
- P325 Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
- P326 An exploratory analysis of the impact of COVID-19 on colonoscopy procedures and new biologic treatment initiation among patients with Inflammatory Bowel Disease in the United States
- P327 Long-term effectiveness of ustekinumab in refractory Crohn's disease: an Italian multicenter real-life study
- P328 Ustekinumab is an effective and safe therapy in anti-TNF refractory Crohn’s Disease: a two year real-life observational study from Spain
- P329 Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
- P330 Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
- P331 The safety of tioguanine exposure during pregnancy: a case series of seventy-three pregnancies
- P332 Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis
- P333 Endoscopic severity and CRP predict failure of medical rescue therapy in patients with acute severe ulcerative colitis
- P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme
- P335 Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort study
- P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained
- P337 Early infliximab clearance predicts remission in children with Crohn’s Disease
- P338 effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of Geteccu
- P339 Pregnant women with perianal Crohn’s Disease: suggestions for the improvement of the current guideline on delivery method
- P340 Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn’s disease: A retrospective cohort database analysis
- P341 Perceived risks and psychosocial burden during the COVID-19 pandemic in a large cohort of pediatric and adult patients with Inflammatory Bowel Disease
- P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique
- P343 Maintenance of deep remission in Crohn’s disease after switching from anti–TNF to ustekinumab.
- P344 Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis
- P345 Food-related quality of life in adults with Inflammatory Bowel Disease is influenced by restrictive eating behaviour, disease activity and surgery: a prospective multi-centre study
- P346 Decreasing disparities in and use of systemic corticosteroid and disparities in use among paediatric patients with Crohn disease in a multicentre collaborative
- P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases
- P348 Perception of cancer risk in inflammatory bowel disease-associated dysplasia and management practice is influenced by colonoscopy experience and workplace affiliation: results of an international clinician survey
- P349 has been withdrawn
- P350 SAFIIR: Study of Anemia Following Intravenous Iron Repletion
- P351 SARS-CoV-2 infection and seroconversion in pediatric patients on biological therapy for Crohn’s disease: single tertiary center experience
- P352 A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The Cross Pennine study II
- P353 Pan-enteric capsule endoscopy enables assessment of mucosal healing after biologic treatment initiation in Crohn’s disease
- P354 Early treatment versus active surveillance after ileocolic resection in Crohn’s disease: a retrospective cohort study.
- P355 Preferences and satisfaction of IBD patients in whom the adalimumab regimen was changed from 40 mg weekly to 80 mg every other week: the ADASCAL study
- P356 A comparison of innovative strategies to promote engagement with an IBD patient portal
- P357 Long-term outcomes of biologic therapy in Crohn’s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU
- P358 An observational, prospective cohort study to evaluate the long term safety and effectiveness of intravenous CT-P13 (biosimilar of infliximab) in patients with Crohn’s Disease or Ulcerative Colitis
- P359 Influence of the nature of immunosuppressive therapy in patients with inflammatory bowel diseases on the level of immunoglobulins G after a Coronavirus Infection
- P360 Aggressive Inflammatory Bowel Disease is associated to Hermansky-Pudlak Syndrome: Characterization of a Puerto Rican Cohort
- P361 No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure
- P362 Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics
- P363 Locally injected allogeneic bone marrow-derived mesenchymal stromal cells for the treatment of refractory proctitis: clinical results of a phase IIa trial
- P364 Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study
- P365 Correlation between patient-reported outcomes (PROs) and patient-reported disease activity in Ulcerative Colitis (UC): Findings from the ICONIC study
- P366 Vedolizumab maintenance therapy reduced use of corticosteroids in patients with Crohn’s disease in the GEMINI 2 trial
- P367 Weight patterns in biologicals treated Inflammatory bowel disease cohort
- P368 Proactive Therapeutic Drug Monitoring is more effective than Conventional Management in Inducing Fecal Calprotectin remission in Inflammatory Bowel Disease
- P369 High prevalence of abdominal pain in Crohn's Disease patients of the TRUST study cohort- Is there a connection to inflammatory activity?
- P370 Concomitant azathioprine prevents new-onset arthralgia after initiation of vedolizumab: A retrospective cohort study
- P371 Using digital monitoring during the COVID pandemic to streamline outpatient appointments
- P372 Effectiveness and safety of immunosuppressants for pouch disorders: results from the RESERVO Study of GETECCU
- P373 Psoriasis and psoriasiform skin lesions in patients with Inflammatory Bowel Disease treated with infliximab: a pharmacokinetic analysis
- P374 Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn’s disease.
- P375 A simulation study to evaluate the performance of a multiple imputation method to address missing data in an analysis of clinical effectiveness using the ImproveCareNow Registry of pediatric patients with Crohn’s disease
- P376 Improving stress and fatigue in a real-world setting among patients with Inflammatory Bowel Disease through a digital platform
- P377 Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database study
- P378 Oxidative status and antioxidant capacity in children and adults with IBD: preliminary results of the OxIBDiet trial
- P379 Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents.
- P380 Comparison of mucosal healing through segments of ileocolonic Crohn’s disease treated with biologics
- P381 Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease
- P382 High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease
- P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study
- P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
- P385 Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown
- P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab
- P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic
- P388 Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative Colitis
- P389 Efficacy and safety of ustekinumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: real clinical practice
- P390 Diverting Loop Ileostomy in Medically Refractory Crohn's Colitis
- P391 Antibiotics in pediatric Inflammatory Bowel Diseases: a systematic review
- P392 A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility study
- P393 Treatment patterns of patients with perianal fistulizing Crohn’s disease from a US administrative claims database
- P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease
- P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
- P396 Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
- P397 Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labeling
- P398 Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with Anaemia
- P399 Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study
- P400 Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patients
- P401 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study
- P402 Is co-trimoxazole prophylaxis necessary for Inflammatory Bowel Disease patients receiving triple immunosuppression?
- P403 Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.
- P404 Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany
- P405 Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients
- P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
- P407 Thiopurines: use them or lose them? Results of an international survey
- P408 Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
- P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, r
- P410 Which patients with established Crohn's disease benefit most from the use of the Patency capsule test prior to small bowel capsule endoscopy?
- P411 Baseline Hypertrophy of the Submucosa at intestinal ultrasound predicts Failure of Treatment in patients with ulcerative colitis
- P412 Effectiveness of ustekinumab in fistulising perianal Crohn´s disease refractory or intolerant to anti-TNF
- P413 Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn`s disease.
- P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
- P415 Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents
- P416 Use of DXA in children with Inflammatory Bowel Disease – a large single centre study
- P417 Long-term deep remission after adalimumab discontinuation in Crohn’s disease patients.
- P418 Does capsule endoscopy impact clinical management in established Crohn’s Disease?
- P419 Psychological acceptability of surgery in patients with ulcerative colitis after total colectomy
- P420 Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemia
- P421 Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study
- P422 COVID 19 infection in IBD patients treated with biologic therapy-experience from tertiary center in Serbia
- P423 Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapies
- P424 Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
- P425 Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)
- P426 Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
- P427 Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
- P428 Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment Protocol
- P429 Continued postoperative use of biologics for the prevention of recurrence of Crohn’s disease
- P430 Prognostic significance of neuropeptide expression in ileal neural plexuses in Crohn’s disease. A retrospective study.
- P431 Teduglutide use and nutritional outcomes in short bowel syndrome with intestinal failure: a real-world claims database analysis
- P432 MyChart application in addressing Inflammatory Bowel Disease patients’ concerns and impact on service utilisation
- P433 Sex-based differences in response to tumor necrosis factor inhibitor induction therapy for ulcerative colitis: a pooled analysis of individual patient-level clinical trials data
- P434 Factors associated with medical and psycosocioeconomic changes in IBD during the COVID-19 pandemic and post-pandemic period
- P435 The impact of perianal fistula in Crohn’s disease on quality of life: results of a patient survey conducted in Europe
- P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
- P437 Hyperbaric oxygen therapy for Inflammatory Bowel Disease – a systematic review
- P438 Maladaptive decision-making is associated with psychological morbidity in people with Inflammatory Bowel Disease.
- P439 Effectiveness of Ustekinumab on Crohn's disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
- P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
- P441 Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn’s disease patients treated with ustekinumab – 1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary
- P442 Serum vedolizumab trough levels are associated with remission rate but not with extra-intestinal manifestations in IBD patients
- P443 Haemorrhoidal Artery Ligation – Recto-Anal Repair (HAL-RAR) with mucopexy for grade III hemorrhoids in IBD patients
- P444 Fecal calprotectin response to anti-tumor necrosis factor alpha induction and maintenance in Pediatric Inflammatory Bowel Disease
- P445 Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
- P446 Plasma rich in growing factors as treatment for perianal fistulas in Crohn’s disease: unicentre experience.
- P447 Combined fibrin glue with infliximab therapy of postoperative anastomotic fistula in patients with Crohn`s disease：A Pilot study
- P448 Safety of anti-TNF introduction following tuberculosis treatment in Inflammatory Bowel Disease patients in an endemic area
- P449 Cost Effectiveness of a Proactive Therapeutic Drug Monitoring Strategy in Patients with Inflammatory Bowel Disease Receiving Infliximab
- P450 Vaccination strategies in Inflammatory Bowel Disease patients: perspective of physicians and patients.
- P451 Efficacy and safety of tofacitinib in the treatment of patients with active, moderate to severe, Ulcerative Colitis: a systematic review and meta-analysis
- P452 Oral ciclosporin is a convenient, effective and safe rescue therapy in steroid refractory Acute Severe Ulcerative Colitis: A single tertiary centre experience
- P453 The use of immunosuppresants is associated with high treatment persistence rates for infliximab and adalimumab as first or second line anti-TNF therapy in patients with inflammatory bowel disease
- P454 Treatment with biologics improves disability from Inflammatory Bowel Disease in therapy responders
- P455 Tofacitinib Therapy is Effective for Arthralgias Associated with Active Inflammatory Bowel Disease
- P456 Ig glycosylation in ulcerative colitis: it's time for new biomarkers
- P457 Long-term follow-up of patients with IBD after switching from original adalimumab to adalimumab biosimilar during COVID 19 pandemic
- P458 Effectiveness of biological therapy for pouchitis and other inflammatory complications ot the pouch. And the question of a second Anti-TNF after failure? Results from the RESERVO Study of GETECCU.
- P459 Change in the expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease
- P460 Biomarkers reflecting extracellular matrix turnover and inflammation can be used to monitor disease activity and treatment response in patients with Crohn’s disease undergoing infliximab induction therapy
- P461 Vedolizumab Dose Escalation in a Real-World Cohort of IBD Patients
- P462 Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study
- P463 COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI Onlus).
- P464 Steroid dependency in patients with Ulcerative Colitis treated with advanced therapies in a German real-world-setting
- P465 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis
- P466 Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab.
- P467 Perception Gap between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study
- P468 Analysis of international spontaneous reporting system databases for safety of corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and consequences of Corticosteroid Excess (DICE)-impact study
- P469 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s disease
- P470 Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients
- P471 Predictors of bowel damage in long term progression of Crohn’s disease
- P472 Payer addressable burden of Crohn’s disease in patients treated with ustekinumab and vedolizumab in the United States
- P473 Ustekinumab and vedolizumab influence on cardiovascular risk factors in patients with Inflammatory Bowel Disease
- P474 Postoperative infectious complications in patients with Inflammatory Bowel Disease: experience of a tertiary center
- P475 Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis
- P476 Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
- P477 Assessment of treatment sequence and real-world outcomes in patients with Ulcerative Colitis
- P478 Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study
- P479 Biological therapies and bio-microbial dynamics in inflammatory bowel diseases
- P480 Assessing primary response to biologic therapy in Inflammatory Bowel Disease - ‘the when and the how?’
- P481 Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project
- P482 Safety and efficacy of ustekinumab for Crohn’s disease in the elderly population
- P483 Infliximab but not adalimumab drug levels predict faecal calprotectin response in Inflammatory Bowel Disease patients on dose-intensified anti-TNF therapy
- P484 Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit
- P485 Development and implementation of a remote monitoring tool for real-world assessment of mild, moderate and severe infectious complications in Inflammatory Bowel Disease patients
- P486 Iron deficiency anaemia in inflammatory bowel disease: Diagnosis, quality of life and iron treatment preferences among European patients
- P487 The feasibility of a digital platform for improving disease management among patients with Ulcerative Colitis
- P488 The COVID19 pandemic impact on Inflammatory Bowel Disease Patients Management in a Romanian Tertiary Gastroenterology Centre
- P489 Rescue treatment with original versus biosimilar infliximab in biologic-naïve patients with moderate-severe Ulcerative Colitis and corticosteroid failure
- P490 The impact of the COVID-19 pandemic on gastroenterologists providing care to inflammatory bowel disease patients in Canada: preliminary data of a cross-sectional survey
- P491 Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease
- P492 The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study
- P493 Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with Inflammatory Bowel Disease
- P494 Can Patients Monitor Response To Ustekinumab In The Real World?
- P495 The interplay of biopsychosocial factors and quality of life in Inflammatory Bowel Diseases: a network analysis
- P496 Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study
- P497 The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn’s disease
- P498 Diagnosing and differentiating iron deficiency in inflammatory disorders: still an unsolved mystery?
- P499 Use of an Inflammatory Bowel Disease illustrated guide as a patient education tool
- P500 Assessing physical activity, fatigue and quality of life in an outpatient cohort of IBD patients
- P501 Incidence and therapeutic management/treatment of very early onset inflammatory bowel disease during 2015-2020.
- P502 Dietary habits and nutritional status in children and adolescents with Inflammatory Bowel Disease: an italian multicenter case-control study (NUTRIBD study)
- P503 Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics
- P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study
- P505 Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound
- P506 The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients
- P507 Vulvar Crohn’s disease: A challenging diagnosis
- P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
- P509 Influence of concomitant immunosuppresives in retention rate in Crohn´s Disease patients under ustekinumab in the SUSTAIN Study
- P510 Postoperative enterocoutaneous fistula after surgery for Crohn’s disease performed in a tertiary centre over 15 years: analysis of the long-term outcomes and predictors of fistula closure
- P511 Disease-specific risk factors for malnutrition development in IBD
- P512 Safety of reduced clinical monitoring in patients with stable Inflammatory Bowel Disease on maintenance thiopurine therapy
- P513 Assessment of quality indicators in The Swedish Inflammatory Bowel Disease Registry (SWIBREG) for Crohn’s Disease treated with biological therapies
- P514 Influence of the frequency of glucocorticosteroid therapy courses on the hormonal resistance in patients with ulcerative colitis.
- P515 A 12-week tailored physical training program including dietary advice in children with Inflammatory Bowel Disease: a randomized crossover trial
- P516 Serological biomarkers of tissue remodeling are associated with endoscopic remission in Crohn’s disease patients treated with GED-0301 (mongersen)
- P517 One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy.
- P518 Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID.
- P519 Impact of skin examination prior to initiation of biological treatment in patients with Inflammatory Bowel Disease: preliminary data
- P520 ‘Eetscore’ in patients with Inflammatory Bowel Disease: an online tool to assess diet quality and provide personalised dietary advice
- P521 Correlation between physician disease assessment in Ulcerative Colitis and burden of disease: ICONIC 2-year data of 120 patients in Turkey
- P522 Effectiveness of tofacitinib in a real-world Israeli cohort of patients with moderate-severe ulcerative colitis
- P523 Survey to identify patient characteristics, treatment preferences and impact of inflammatory bowel disease (IBD) on quality of life across 7 countries in Europe
- P524 Endoscopic dilations of intestinal stenosis in Crohn's disease
- P525 Patients' Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Di
- P526 Social functioning, work-productivity and psychological assessment in a cohort of patients with inflammatory bowel disease: an observational study
- P527 Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
- P528 Reducing intravenous monoclonal antibody observation times without compromising patient safety; a single-centre observational study.
- P529 Adalimumab persistence and its biosimilar in inflammatory bowel disease: experience in a tertiary centre
- P530 Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's disease
- P531 SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study.
- P532 Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic
- P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
- P534 has been withdrawn
- P535 Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidence
- P536 Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease.
- P537 Anemia in Crohn's Disease: Response to treatment and risk of recurrence
- P538 The reliability of patient performed fecal calprotectin testing
- P539 Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)
- P540 Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literature
- P541 Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown.
- P542 Clinical presentation, disease behavior and management of inflammatory bowel disease at extremes of age
- P543 The role of social support on psychological distress and health-related quality of life in adults with mild to moderately active Crohn's disease.
- P544 Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrations
- P545 Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab
- P546 The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype
- P547 Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysis
- P548 Drug Survival in Patients with Inflammatory Bowel disease: An observational study
- P549 Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.
- P550 Short term effects of a combined lifestyle intervention in patients with Inflammatory Bowel Disease
- P551 Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn’s disease.
- P552 Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
- P553 Factors related to steroid consumption in IBD patients: Evidence from a multicenter Study
- P554 Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?
- P555 Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease
- P556 Safety and efficacy of ustekinumab in the treatment of Crohn's Disease: A systematic review and meta-analysis
- P557 Long-term outcomes following laparoscopic ileocecal resection without any residual lesion for Crohn’s disease: a single-center observational study
- P558 Medication Preference of 400 patients with mild to moderate Ulcerative Colitis
- P559 Efficacy of Ustekinumab in the treatment of patients with Crohn’s disease with failure to previous conventional or biologic therapy: an observational real-life study
- P560 Clinical outcomes of vedolizumab maintenance treatment for Korean patients with inflammatory bowel disease who failed anti-TNF therapy: A KASID prospective multicenter cohort study
- P561 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in predicting the therapeutic effect of mesalazine in UC patients.
- P562 Web-based questionnaire survey about self-management for patients with Inflammatory Bowel Disease in Japan
- P563 Comparison of long-term outcomes of infliximab with adalimumab in biologic naïve patients with Crohn’s disease: a tertiary referral center 13-year experience.
- P564 Validation of the IBD-Disk instrument in a Portuguese cohort
- P565 Illness perception as a clinical tool to detect mood disturbances (anxiety or depression) in inflammatory bowel disease patients.
- P566 Impact of induction therapy and clinical remission on resting energy expenditure in children with Crohn’s Disease
- P567 Pharmacist-managed immunomodulator clinic in titration and monitoring of immunosuppressants in Inflammatory Bowel Disease
- P568 Effectiveness of ustekinumab after vedolizumab failure in patients with anti-TNF-refractory Crohn’s disease.
- P569 Online education significantly improved gastroenterologists' knowledge of management strategies and treatment options for ulcerative colitis.
- P570 Prediction of achieving remission in Crohn's disease patients by abdominal Imaging
- P571 Optimal biologic management of endoscopic postoperative recurrence following ileocecal resection in Crohn’s disease
- P572 The influence of beliefs about medication in therapeutic adherence among patients with inflammatory bowel disease.
- P573 Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
- P574 Exploring treatment of Crohn’s disease and ulcerative colitis in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study
- P575 Nutrition and Inflammatory Bowel Disease – a nationwide survey of patients, gastroenterologists and dietitians
- P576 Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients.
- P577 Withdrawal of thiopurines in patients with Ulcerative Colitis in remission
- P578 Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients
- P579 Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis
- P580 Benchmarking IBD Pharmacy Services to optimise, strengthen and align IBD Expert Pharmacy Practice
- P581 Pre-operative prolonged antibiotic treatment in ileocecal Crohn’s disease: single center non-randomized prospective study.
- P582 Insights on the sphingolipid profile in patients with short bowel syndrome and consecutive intestinal failure
- P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study
- P584 Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis
- P585 IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspective.
- P586 Drug-induced lipid changes in patients with Inflammatory Bowel Disease: a single center, prospective study
- P587 Utility of intestinal ultrasound in Inflammatory Bowel Disease patients on management decisions
- P588 Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients
- P589 Stable Trends in Radiation Exposure Amongst Patients with a New Diagnosis of Inflammatory Bowel Disease at an Irish Tertiary Referral Hospital
- P590 Which biomarkers have an effect on therapeutic vedolizumab drug levels? A retrospective analysis from a London Tertiary Centre.
- P591 Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB).
- P592 Costs savings associated with ferric maltol and the reduced use of intravenous iron based on real world data
- P593 Ustekinumab for the treatment of perianal Crohn’s disease. A real-world experience in a Spanish hospital
- P594 Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience
- P595 Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease
- P596 Trough concentration of ustekinumab was a useful biomarker for the prediction of treatment-effects in patients with Crohn’s Diseases.
- P597 Cycling Anti-TNF Therapy in Inflammatory Bowel Disease: Effectiveness and Durability of Switching from adalimumab to infliximab
- P598 Previous Intestinal Resection Is Associated with Postoperative Complications in Crohn’s Disease: A Cohort Study
- P599 Perspectives on disease- and treatment-related issues encountered by patients with Inflammatory Bowel Disease: a qualitative concept mapping study
- P600 Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
- P601 Are Inflammatory Bowel Disease patients’ expectations met by dietetic services?
- P602 Vedolizumab subcutaneous influencing disease course in Constant-care app solution
- P603 Patient characteristics and adverse effects in biologic treatment of Crohn’s Disease and Ulcerative Colitis: A nationwide Danish cohort study years 2015-2018.
- P604 Evaluation of management heterogeneity and complications of Crohn’s disease in Catalonia. A population quality care study
- P605 Development and validation of an objective disability index for Inflammatory Bowel Disease patients (ODIBD)
- P606 Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU.
- P607 The Faroese IBD Study: Update on incidence from 2015-2020 and prevalence from 1960-2020
- P608 Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
- P609 Impact of accessibility of medical care and socioeconomic class on outcomes of IBD – a nationwide population study
- P610 Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions
- P611 Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection
- P612 Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study.
- P613 Social Media Analytics for Inflammatory Bowel Disease – What Are We Missing?
- P614 A strategy to solve complexity of physician diagnosis using a mixture of Patient Reports and Provider Reports: A Case Study of Crohn’s Disease Phenotypes
- P615 Does smoking really influence the development and the outcomes of Inflammatory Bowel Disease in Asian population? Results from the Taiwanese patients
- P616 Sustainability of thiopurines monotherapy in ulcerative colitis: a nationwide analysis from the epi-IIRN cohort
- P617 Trends in Pediatric Inflammatory Bowel Disease-attributable direct costs: A Canadian population-based analysis
- P618 Treatment outcomes of patients with Crohn’s disease and complex perianal fistula in five European countries: the PREFACE retrospective study
- P619 has been withdrawn
- P620 Pivoting in a pandemic: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease – A retrospective study
- P621 Lactose intolerance assessed by analysis of genetic polymorphism, breath test and symptoms in patients with inflammatory bowel disease
- P622 Comparison of midterm outcomes in Pediatric Crohn’s Disease patients treated with either Exclusive Enteral Nutrition or Corticosteroids around disease diagnosis– a population based study
- P623 The impact of SARS-CoV-2 outbreak on the treatment adherence and clinical outcome of patients with inflammatory bowel disease treated with biological agents.
- P624 A higher prevalence of human papillomavirus in patients with perianal fistulizing Crohn's disease compared to patients with anorectal fistula without Crohn's disease.
- P625 Characteristics of SARS-CoV-2 infection in IBD patients in the second and third wave compared with the first wave and with the data of general population
- P626 SARS-CoV-2 seroprevalence in patients with Inflammatory Bowel Disease
- P627 Change in urgency among ulcerative colitis patients: Analyses from the SPARC IBD
- P628 Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases
- P629 Rural-urban inequities in Inflammatory Bowel Disease health care access: a population-based retrospective cohort study from a Western Canadian Province
- P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)
- P631 Food triggers in inflammatory bowel disease from the patients’ and doctors’ perspective
- P632 Is the gender or age of the physician key to a good physician-patient with Inflammatory Bowel Disease relationship?
- P633 Clinical epidemiology of Inflammatory Bowel Disease in Lbanon
- P634 Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients
- P635 Assessment of sarcopenia and nutritional status in a cohort of patients with Crohn’s disease
- P636 The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD.
- P637 Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting
- P638 Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
- P639 Epidemiology and patient burden of rectovaginal and anovaginal fistulas in patients with Crohn’s disease: A systematic review
- P640 Characteristics of elderly onset Inflammatory Bowel Disease in a cohort of Hispanics
- P641 Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease
- P642 Effects of Covid-19 on employment in IBD patients
- P643 Patient perspectives and expectations in inflammatory bowel disease: a systematic review
- P644 Hospitalization and abdominal surgery rates in CD according to drug-dispensing: a temporal trend analysis from the Brazilian public healthcare national system
- P645 Mental health, work presenteeism and exercise in IBD patients
- P646 The Loss of Productivity in Employment and Education Associated to Inflammatory Bowel Diseases: A Pilot Study of the Patient’s Perception
- P647 Awareness, knowledge and use of mesenchymal stem cells – a global survey among gastroenterologists and colorectal surgeons
- P648 Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease
- P649 Ulcerative Colitis Narrative Japanese survey: Identifying gaps between patient and healthcare professional perspectives on communication and disease management to optimise patient care
- P650 A trend to higher adoption of mesalazine suppository use for UC patients in 15 European countries
- P651 Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn’s disease: data from administrative databases in Tuscany, Italy
- P652 Treatment patterns in patients receiving outpatient care for inflammatory bowel disease in Russian Federation
- P653 Rheumatic extraintestinal manifestations in ulcerative colitis : Prevalence and predictive factors
- P654 Prevalence of Inflammatory Bowel Disease in young Greek Army male recruits from 2006 to 2018: a thirteen-year retrospective study from a tertiary center
- P655 Insulin Resistance Prevalence is Not Increased in Patients with Inflammatory Bowel Disease: a case-control study
- P656 Epidemiology and outcomes associated with local surgical and intersphincteric ligation procedures for complex cryptoglandular fistulas: A systematic literature review
- P657 Acceptability of a COVID-19 vaccine among cohort of Croatian IBD patients treated in tertiary IBD centre
- P658 Is vitamin D deficiency related to fat malabsorption or inflammation in Inflammatory Bowel Disease? Preliminary results from the Fat-D study
- P659 Colonoscopic screening of symptomatic patients suggests an emerging inflammatory bowel disease (IBD) in urban and rural south India
- P660 The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease: A cross sectional survey
- P661 Radon exposure and inflammatory bowel disease in a radon prone area
- P662 A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use
- P663 Long-term follow up in IBD: 10-year observational study of a UK IBD cohort.
- P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
- P665 Cardiovascular risk profile in chronic auto-inflammatory diseases: a cross-sectional single center study
- P666 Frequency and outcome of SARS-CoV2 infection in patients with inflammatory bowel disease on different biological therapy
- P667 Characterization of a large Hispanic cohort with Inflammatory Bowel Disease across a 25-year span
- P668 Does biotin deficiency play a role in the pathogenesis of Inflammatory Bowel Disease? Preliminary results of a cross-sectional study
- P669 Effect of vedolizumab therapy on whole blood transcriptional profiles in patients with Inflammatory Bowel Disease
- P670 Identification of two additional susceptibility loci for Crohn's disease in Koreans
- P671 Effect of genetic polymorphisms in the folate pathway on the efficacy and safety of methotrexate in Crohn’s disease.
- P672 A tertiary multicenter cohort of patients with chronic intestinal pseudo-obstruction and Crohn’s disease: a rare association with a high prevalence of monogenic disorders.
- P673 Microbial diversity in newly diagnosed treatment naïve Inflammatory Bowel Disease patients
- P674 Definition of a microbial signature as a predictor of anti-TNFα treatment response
- P675 Flavonoid-degrading bacteria have central positions in correlation network analysis in patients with Inflammatory Bowel Disease
- P676 The small intestinal microbiome in Crohn’s disease is characterised by increased luminal diversity and stable mucosa-associated communities
- P677 Fungal abundance is related to inflammatory status in Ulcerative Colitis
- P678 Definition of a microbial signature as a predictor of post-surgical recurrence in patients with Crohn's disease
- P679 The keystone bacterium Christensenella minuta improves colitis in in vivo preclinical Inflammatory Bowel Disease models
- P680 Similar gut bacterial composition between patients with ulcerative colitis and healthy controls in a high prevalence population: a cross-sectional study of the Faroe Islands IBD cohort
- P681 Higher in vitro mucin degradation, but no increased paracellular permeability by faecal water from Crohn’s disease patients
- P682 Antibiotic resistome profiles of fecal Escherichia coli isolates in association with Crohn’s disease
- P683 Patients with newly diagnosed fistulizing perianal Crohn's disease have a distinct microbial signature
- P684 Multiplex Gastrointestinal Pathogen Panel Testing is Associated with Higher Rates of Inflammatory Bowel Disease Therapy Escalation in Patients Hospitalised with Flare
- P685 Gut microbiota in patients with Inflammatory Bowel Disease during remission
- P686 Novel grape-derived prebiotic selectively enhances abundance and metabolic activity of IBD and IBS faecal butyrate producing bacteria in an in vitro model of intestinal fermentation
- P687 Development of a panel of microbial markers to distinguish transient from pathological dysbiosis
- P688 Association of Akkermansia muciniphila with a healthy gut microbiome
- P689 Aeromonas infection and Inflammatory Bowel Disease: a single tertiary center analysis
- P690 Changes of intestinal microbiota in patients with inflammatory bowel diseases
- N01 Does physical activity positively impact fatigue in individuals with Inflammatory Bowel Disease?
- N02 PREVIEW study: Factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with Inflammatory Bowel Disease.
- N03 Information flow experiences during COVID-19 in IBD patients: a prospective observational study
- N04 Being an IBD Clinical Nurse Specialist in the UK National Health Service: Challenges, Stressors and Coping Mechanisms
- N05 A Systematic Review of Self-Management Intervention Study for Patients with Inflammatory Bowel Disease
- N06 Patient perspectives on the role of the IBD nurse and telemedicine during COVID-19 pandemic: results from a Belgian tertiary IBD unit
- N07 a qualitative study of the impact of inflammatory bowel disease on partners
- N08 Construction of an explanatory model for quality of life in outpatients with ulcerative colitis
- N09 Sexuality as lived incompleteness: exploring intimacy and sexuality experiences of people living with inflammatory bowel disease
- N10 Experience with telemedicine during the COVID-19 pandemic and preferences for future e-health in a large IBD cohort
- N11 Complementary and alternative methods to improve quality of life in patients with inflammatory bowel diseases: a systematic literature review
- N12 A decade of waiting to know is not good enough! Experiences of women with vulval Crohn’s disease
- N13 Living in rural communities with Inflammatory Bowel Disease: Perspectives on healthcare use and access to care from patients and providers in one Canadian province
- N14 The Effectiveness of patient information leaflets provided by a Clinical Nurse Specialist on disease related knowledge in Inflammatory Bowel Disease
- N15 Transition of care programme and treatment adherence in adolescents with Inflammatory Bowel Disease
- N16 ‘Sex? Don't even remember what that is …’ exploring IBD patient engagement with online forums regarding the topics of relationships and intimacy
- N17 The Perceptions and Experiences of People Living with Inflammatory Bowel Disease of Nursing Care A Qualitative Evidence Synthesis
- N18 Multidisciplinary team importance in the view of the patients with Inflammatory Bowel Disease in Brazil